Arcutis Biotherapeutics, Inc.

This study looked at the long-term safety of a cream called roflumilast for people with mild to moderate eczema (atopic dermatitis). Over 1,200 participants, ages 2 and up, applied the cream once daily for up to 52 weeks. The main goal was to track any side effects, with secondar…

This early-phase study tested a medicated foam called ARQ-154 (roflumilast) in 22 children aged 2 to 12 with scalp and body psoriasis. The goal was to see how much of the drug enters the bloodstream and whether it is safe. Researchers monitored side effects and skin reactions ove…

This study tested a cream called ARQ-151 on 652 children aged 2 to 5 with eczema (atopic dermatitis). The cream was applied once daily for 4 weeks. The goal was to see if it could clear or nearly clear the skin rash better than a cream with no active ingredient. The study is comp…

This study tested a cream called roflumilast (0.05%) applied once daily for 4 weeks in 101 infants aged 3 months to 2 years with mild-to-moderate eczema. The main goal was to see if the cream is safe and well-tolerated. Researchers tracked side effects, serious side effects, and …